Oils and fats for improving glucose metabolism disorders and oils and fats for improving intestinal environment

Abstract

To provide oils and fats for improving glucose metabolism disorders and oils and fats for improving intestinal environment.SOLUTION: Provided are oils and fats for improving glucose metabolism disorders and oils and fats for improving intestinal environment, comprising oil and fat compositions containing 10 mass% or more and 30 mass% or less of palmitic acids, among all constituent fatty acid residues in the oil and fat compositions. Of the palmitic acids, those bound at the 2-position accounts for 50 mass% or more.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to an oil or fat for improving abnormal glucose metabolism and an oil or fat for improving intestinal environment. [Background technology]

[0002] Ingestion of large amounts of lard, a typical animal fat, can cause malformations such as inflammation in peripheral tissues (intestines and adipose tissue) and abnormal glucose metabolism. One of the factors that cause these malformations is changes in the intestinal flora and the production of its metabolic products, as well as changes in the relationship between IgA, the main antibody secreted in the intestine, and intestinal bacteria.

[0003] For example, Non-Patent Document 1 observes that ingestion of a high-lard diet tends to weaken the binding between intestinal IgA and intestinal bacteria, and suggests that this is one of the causes of glucose metabolism disorders.

[0004] Furthermore, Non-Patent Document 2 describes that when a diet high in lard is ingested, some intestinal bacteria belonging to the Lachnospiraceae family produce elaidic acid, which causes a decrease in barrier function and abnormalities in sugar metabolism. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] T. Tsuruta, TA Muhomah, K. Sonoyama, Q. D. Nguyen, Y. Takase, A. Nishijima, S. Himoto, E. Katsumata, N. Nishino, Nutrition Research 2021, 93, 15. [Non-Patent Document 2] T. Takeuchi, K. Kameyama, E. Miyauchi, Y. Nakanishi, T. Kanaya, T. Fujii, T. Kato, T. Sasaki, N. Tachibana, H. Negishi, Cell Metabolism 2023, 35, 361. Summary of the Invention [Problem to be solved by the invention]

[0006] An object of the present invention is to provide an oil or fat for improving abnormal glucose metabolism and an oil or fat for improving intestinal environment. [Means for solving the problem]

[0007] The present invention solves the above problems, The oil composition contains palmitic acid in an amount of 10% by mass or more and 30% by mass or less of all the constituent fatty acid residues of the oil composition, and of the palmitic acid, 50% by mass or more of the palmitic acid is bonded to the 2-position. This oil composition is for improving abnormal sugar metabolism. The oil or fat for improving abnormal sugar metabolism comprising the above-mentioned oil or fat composition can improve abnormal sugar metabolism.

[0008] In a preferred embodiment of the present invention, the oil composition contains medium-chain fatty acids among all the constituent fatty acid residues of the oil composition.

[0009] In a preferred embodiment of the present invention, abnormal glucose metabolism is improved by promoting binding between enterobacteria and IgA in the intestine.

[0010] In a preferred embodiment of the present invention, the oil / fat composition contains, among the triglycerides constituting the oil / fat composition, a total of 50 mass % or more of triglycerides each having two molecules of medium-chain fatty acid and one molecule of long-chain fatty acid bonded thereto, and triglycerides each having one molecule of medium-chain fatty acid and two molecules of long-chain fatty acid bonded thereto.

[0011] In a preferred embodiment of the present invention, the oil and fat composition is an oil and fat composition obtained by 1,3-position specific interesterification of the following raw oil and fat compositions (A) and (B). (A) Triglyceride containing 70% by mass or more of medium-chain fatty acids among all the constituent fatty acid residues (B) A triglyceride containing 15 mass% or more of palmitic acid among all of the constituent fatty acid residues.

[0012] In a preferred embodiment of the present invention, the medium-chain fatty acid is caprylic acid and / or capric acid.

[0013] The present invention also relates to an oral or parenteral composition comprising the above-mentioned oil or fat for improving abnormal glucose metabolism.

[0014] The present invention also relates to an oil or fat for improving intestinal environment, comprising an oil or fat composition containing palmitic acid in an amount of 10% by mass or more and 30% by mass or less of all constituent fatty acid residues of the oil or fat composition, and in which palmitic acid bonded to the 2-position accounts for 50% by mass or more of the palmitic acid. The intestinal environment can be improved by the above-mentioned oils and fats for improving the intestinal environment.

[0015] In a preferred embodiment of the present invention, the oil composition contains medium-chain fatty acids among all the constituent fatty acid residues of the oil composition.

[0016] In a preferred embodiment of the present invention, the oil for improving intestinal environment is an oil for promoting binding between intestinal bacteria and intestinal IgA.

[0017] In a preferred embodiment of the present invention, the oil for improving intestinal environment is an oil for suppressing intestinal inflammation.

[0018] In a preferred embodiment of the present invention, the oil / fat composition contains, among the triglycerides constituting the oil / fat composition, a total of 50 mass % or more of triglycerides each having two molecules of medium-chain fatty acid and one molecule of long-chain fatty acid bonded thereto, and triglycerides each having one molecule of medium-chain fatty acid and two molecules of long-chain fatty acid bonded thereto.

[0019] In a preferred embodiment of the present invention, the oil and fat composition is an oil and fat composition obtained by 1,3-position specific interesterification of the following raw oil and fat compositions (A) and (B). (A) Triglyceride containing 70% by mass or more of medium-chain fatty acids among all the constituent fatty acid residues (B) A triglyceride containing 15 mass% or more of palmitic acid among all of the constituent fatty acid residues.

[0020] In a preferred embodiment of the present invention, the medium-chain fatty acid is caprylic acid and / or capric acid.

[0021] The present invention also relates to an oral or parenteral composition comprising the above-mentioned oil or fat for improving intestinal environment. Effect of the Invention

[0022] The sugar metabolism improver of the present invention can effectively improve sugar metabolism, and the oil for improving intestinal environment of the present invention can effectively improve the intestinal environment. [Brief description of the drawings]

[0023] [Figure 1] Graph showing the final body weight of each mouse group (body weight after 8 weeks of feeding) [Diagram 2] Graph showing the weight of testicular adipose tissue in each mouse group after 8 weeks of feeding [Diagram 3] Graph showing feeding amount (g / day / mouse) [Figure 4] Graph showing the results of oral glucose tolerance test (IAUC for groups A to D) [Diagram 5] Graph showing IAUC in insulin tolerance test [Figure 6] Representative figures of flow cytometer analysis [Figure 7] Graph showing IgA coating rate in groups A to D [Figure 8] Graph showing elaidic acid concentration in feces of mice in groups A to D [Figure 9] Graph showing active GLP1 concentration in plasma of mice in groups A to D [Figure 10] Graph showing CXCL1 mRNA expression levels in mice from groups A to D DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] The present invention will be described in detail below, but the present invention is not limited to the following description.

[0025] <Oil composition> The oil and fat for improving abnormal glucose metabolism and the oil and fat for improving intestinal environment according to the present invention comprise an oil and fat composition. The oil composition according to the present invention contains palmitic acid in an amount of 10% by mass to 30% by mass of all the constituent fatty acid residues of the oil composition, and of the palmitic acid, 50% by mass or more of the palmitic acid is bonded to the 2-position.

[0026] The palmitic acid content in the total fatty acid residues constituting the oil composition is preferably 15% by mass or more, more preferably 20% by mass or more, and the palmitic acid content in the total fatty acid residues constituting the oil composition is preferably 25% by mass or less.

[0027] Of the palmitic acids in all the constituent fatty acid residues of the oil composition, the palmitic acid bonded to the 2-position is preferably 55% by mass or more, more preferably 60% by mass or more, and even more preferably 65% ​​by mass or more. Of the palmitic acids in all the constituent fatty acid residues of the oil composition, the palmitic acid bonded to the 2-position is preferably 100% by mass or less, more preferably 90% by mass or less, even more preferably 80% by mass or less, and particularly preferably 70% by mass or less.

[0028] The oil composition according to the present invention contains medium-chain fatty acids in the total fatty acid residues constituting the oil composition. The content of medium-chain fatty acids in the total fatty acid residues constituting the oil composition is preferably 5% by mass or more, more preferably 10% by mass or more, and even more preferably 15% by mass or more. The content of medium-chain fatty acids in the total fatty acid residues constituting the oil composition is preferably 30% by mass or less, more preferably 25% by mass or less, and even more preferably 20% by mass or less.

[0029] When the medium-chain fatty acid is contained in an amount equal to or greater than the lower limit, the fats and oils are easily digested and absorbed. On the other hand, if the medium-chain fatty acid content is too high, there is concern that the irritation caused by the medium-chain fatty acid may cause gastrointestinal disorders after ingestion, and therefore the content of the medium-chain fatty acid is preferably equal to or less than the above upper limit.

[0030] Examples of medium-chain fatty acids include caproic acid, caprylic acid, capric acid, and lauric acid. However, it is particularly preferable that the fatty acid contains caprylic acid and capric acid.

[0031] Furthermore, in the oil and fat composition according to the present invention, the total of triglycerides constituting the oil and fat composition, that is, triglycerides (M2L) in which two molecules of medium-chain fatty acid (M) and one molecule of long-chain fatty acid (L) are bonded, and triglycerides (ML2) in which one molecule of medium-chain fatty acid (M) and two molecules of long-chain fatty acid (L) are bonded, is preferably 50% by mass or more, more preferably 55% by mass or more.

[0032] The breakdown of M2L and ML2 is preferably M2L:ML2=20:80 to 45:55, and more preferably 25:75 to 40:60.

[0033] In this specification, a medium-chain fatty acid refers to a fatty acid having 6 to 12 carbon atoms, and a long-chain fatty acid refers to a fatty acid having 14 or more carbon atoms.

[0034] When M2L or ML2 is included, the medium-chain fatty acid residues are hydrolyzed in the stomach to form monoglycerides or diglycerides, which favors micelle formation in the small intestine. Even if the fatty acid is not hydrolyzed in the stomach, it is easily degraded by lipase in the small intestine.

[0035] <Method of producing oil composition> The oil and fat composition according to the present invention is preferably an oil and fat composition obtained by 1,3-position specific interesterification of the following raw oil and fat compositions (A) and (B). (A) Triglyceride containing 70% by mass or more of medium-chain fatty acids among all the constituent fatty acid residues (B) A triglyceride containing 15 mass% or more of palmitic acid among all of the constituent fatty acid residues. By subjecting the raw oil and fat compositions (A) and (B) to 1,3-specific ester exchange, an oil and fat composition can be produced which contains 10% by mass or more and 30% by mass or less of palmitic acid among all the constituent fatty acid residues of the oil and fat composition, of which 50% by mass or more of palmitic acid is bonded to the 2-position, and which contains medium-chain fatty acids.

[0036] The raw oil and fat composition (A) contains medium-chain fatty acids in the total constituent fatty acid residues, preferably 70% by mass or more, more preferably 80% by mass or more, even more preferably 90% by mass or more, and particularly preferably 95% by mass or more. When the amount of medium-chain fatty acids is within the above range, an oil and fat composition containing M2L and ML2 can be efficiently obtained.

[0037] The raw oil-and-fat composition (B) preferably contains palmitic acid in its constituent fatty acid residues in an amount of 15% by mass or more, more preferably 20% by mass or more, and preferably contains palmitic acid in its constituent fatty acid residues in an amount of 50% by mass or less, more preferably 40% by mass or less, and even more preferably 30% by mass or less. In addition, of the palmitic acid contained in all the constituent fatty acid residues, the palmitic acid bonded to the 2-position of the glyceride is preferably 50% or more, more preferably 60% or more, and even more preferably 70% or more. By using the raw oil-and-fat composition (B) having the 2-position palmitic acid bond ratio in the above range, micelles can be efficiently formed, and an oil-and-fat composition with good absorbency can be obtained. Examples of the oil and fat composition (B) include lard and structured lipids in which the bond ratio of palmitic acid at the 2-position is increased by an enzymatic 1,3-transesterification reaction.

[0038] The mixing mass ratio of the raw oil and fat compositions (A) and (B) in the 1,3-specific transesterification reaction is preferably 3:7 to 1:9, more preferably 2.5:7.5 to 1.5:8.5.

[0039] In addition, for the transesterification reaction using a 1,3-specific lipase, it is preferable to use a lipase derived from a microorganism of the genus Alcaligenes, Diothorium, Chromobacterium, Rhizopus, Aspergillus, Penicillium, Candida, Pseudomonas, Mucor, or Diotrichum.

[0040] Such lipase can be a commercially available one. Examples include Amano A (manufactured by Amano Pharmaceutical Co., Ltd.) and Lipozyme (manufactured by Novozymes). The form of use of the lipase is not particularly limited, but from the viewpoint of efficiency, it is preferable to immobilize the lipase on a carrier by a conventional method before use.

[0041] The temperature of the enzyme reaction is generally 10°C or higher, more specifically, preferably 30 to 70°C, more preferably 40 to 70°C, and even more preferably 45 to 65°C, from the viewpoints of maintaining the enzyme activity for a long time while ensuring a sufficient reaction rate and of suppressing the production of isomeric triglycerides as much as possible. The time for the enzyme reaction is not particularly limited as long as a sufficient transesterification reaction rate can be achieved, but is preferably 30 minutes or more, and more preferably 2 to 24 hours.

[0042] <Oils and fats for improving glucose metabolism abnormalities> The present invention relates to an oil or fat for improving abnormal glucose metabolism, comprising the above-mentioned oil or fat composition.

[0043] The present invention relates to an oil or fat for improving abnormal glucose metabolism, which can improve abnormal glucose metabolism, preferably without accompanying weight loss. Elderly people and people with certain diseases have a need to avoid losing weight. The present invention relates to an oil or fat for improving abnormal glucose metabolism that can be provided to people with such a need.

[0044] <Methods for improving glucose metabolism abnormalities> Furthermore, the oil or fat for improving abnormal glucose metabolism according to the present invention can improve abnormal glucose metabolism. In other words, the present invention is also a method for improving abnormal sugar metabolism, comprising using an oil composition as an oral or parenteral composition, the oil composition containing 10% by mass or more and 30% by mass or less of palmitic acid among all the constituent fatty acid residues of the oil composition, and the palmitic acid bonded to the 2-position being 50% by mass or more of the palmitic acid.

[0045] Furthermore, the present invention relates to a method for improving abnormal glucose metabolism, which can improve abnormal glucose metabolism preferably without accompanying weight loss.

[0046] <Oils and fats for improving intestinal environment> The present invention also relates to an oil or fat for improving intestinal environment, comprising the above-mentioned oil or fat composition. More specifically, the present invention relates to an oil or fat for promoting binding between intestinal bacteria and intestinal IgA, comprising the above-mentioned oil or fat composition. By promoting the binding between intestinal bacteria and intestinal IgA, the intestinal environment can be improved. More specifically, the present invention relates to an oil or fat for suppressing intestinal inflammation, comprising the above-mentioned oil or fat composition. By suppressing intestinal inflammation, the intestinal environment can be improved.

[0047] The present invention relates to an oil or fat for improving intestinal environment, which can improve abnormal glucose metabolism, preferably without causing weight loss. Elderly people and people with certain diseases have a need to avoid losing weight. The present invention provides an oil and fat for improving the intestinal environment that can be provided to people with such a need.

[0048] <How to improve your intestinal environment> Furthermore, the intestinal environment can be improved by the oil or fat for improving the intestinal environment according to the present invention. In other words, the present invention also relates to a method for improving an intestinal environment, which comprises using an oil composition as an oral or parenteral composition, the oil composition containing 10% by mass or more and 30% by mass or less of palmitic acid among all the constituent fatty acid residues of the oil composition, and the palmitic acid bonded to the 2-position being 50% by mass or more of the palmitic acid.

[0049] The present invention also relates to an oil or fat for improving the intestinal environment, which can improve the intestinal environment preferably without causing weight loss.

[0050] Furthermore, the oil or fat for promoting the binding between intestinal bacteria and intestinal IgA according to the present invention can promote the binding between intestinal bacteria and intestinal IgA. In other words, the present invention also relates to a method for promoting binding between intestinal bacteria and intestinal IgA, which comprises using an oil composition as an oral or parenteral composition, the oil composition containing 10% by mass or more and 30% by mass or less of palmitic acid among all the constituent fatty acid residues of the oil composition, and the palmitic acid bonded to the 2-position being 50% by mass or more of the palmitic acid.

[0051] The present invention also provides a method for promoting the binding between intestinal bacteria and intestinal IgA, which can promote the binding between intestinal bacteria and intestinal IgA preferably without causing weight loss.

[0052] Furthermore, the oil or fat for inhibiting intestinal inflammation according to the present invention can inhibit intestinal inflammation. In other words, the present invention also relates to an oil or fat for suppressing intestinal inflammation, which includes the use, as an oral or parenteral composition, of an oil or fat composition containing 10% by mass or more and 30% by mass or less of palmitic acid in all of the constituent fatty acid residues of the oil or fat composition, and of the palmitic acid bound to the 2-position, 50% by mass or more of the palmitic acid.

[0053] The present invention also relates to an oil or fat for inhibiting intestinal inflammation, which can inhibit intestinal inflammation preferably without causing weight loss.

[0054] <Oral or parenteral compositions> The present invention also relates to an oral or parenteral composition comprising the above-mentioned oil or fat for improving abnormal glucose metabolism, or the above-mentioned oil or fat for improving intestinal environment.

[0055] Oral compositions include foods and medicines. The content of the oils and fats for improving abnormal glucose metabolism or the oils and fats for improving intestinal environment in the oral composition is preferably 2% by mass or more, more preferably 5% by mass or more, even more preferably 10% by mass or more, and particularly preferably 20% by mass or more. The content of the oils and fats for improving abnormal glucose metabolism or the oils and fats for improving intestinal environment in the oral composition is preferably 60% by mass or less, more preferably 50% by mass or less, and even more preferably 40% by mass or less.

[0056] Examples of parenteral compositions include compositions for gastrostomy and enteral compositions. The content of the oils and fats for improving abnormal glucose metabolism or the oils and fats for improving intestinal environment in the parenteral composition is preferably 2% by mass or more, more preferably 5% by mass or more, even more preferably 10% by mass or more, and particularly preferably 20% by mass or more. The content of the oils and fats for improving abnormal glucose metabolism or the oils and fats for improving intestinal environment in the parenteral composition is preferably 60% by mass or less, more preferably 50% by mass or less, and even more preferably 40% by mass or less. EXAMPLES

[0057] The present invention will now be described in more detail with reference to examples.

[0058] <Oil composition> The oil and fat compositions used in the examples and comparative examples will be described below. ·lard Lard (made by Kaneka) was used. ·MPO oil and fat Medium-chain fatty acid oil (manufactured by Chuo Kasei) and the lard described above were mixed in a mass ratio of 22:78, the temperature was adjusted to 55°C, and the mixture was passed through a column packed with 1,3-specific lipase (Lipozyme TL IM, manufactured by Novozymes) to carry out an interesterification reaction. The product that was then decolorized and deodorized is hereafter referred to as MPO.

[0059] <Analysis of triglyceride fraction> The triglyceride fractions of lard and MPO were analyzed by the following methods, which are described in detail below.

[0060] The content of palmitic acid, the total content of caprylic acid and capric acid, and the content of elaidic acid in the total fatty acid residues constituting the oil composition (%) Measurements were performed based on the Standard Method for Fats and Oils Analysis (2.2.4.3-2013, trans fatty acid content (capillary gas chromatography method)). The gas chromatography device used was a GC-2010 model manufactured by Shimadzu Corporation. The column used was an SP-2560 manufactured by SUPELCO.

[0061] 2-Palmitic acid bond ratio (%) The content of palmitic acid bound to the 2nd position of triglyceride was measured based on the standard method for fat and oil analysis (2.4.5-2016, triacylglycerol 2nd position fatty acid composition (enzymatic transesterification method)). The gas chromatography device used was a GC-2010 model manufactured by Shimadzu Corporation. The column used was an SP-2560 manufactured by SUPELCO. The binding ratio of palmitic acid to the 2-position was calculated using the following formula. 2-position palmitic acid bond ratio (%) = (content of palmitic acid bonded to 2-position / content of palmitic acid in all constituent fatty acid residues × 3) × 100

[0062] The total ratio (M2L+ML2) of triglycerides in which two molecules of medium-chain fatty acids and one molecule of long-chain fatty acids are bonded to each other (M2L) and triglycerides in which one molecule of medium-chain fatty acids and two molecules of long-chain fatty acids are bonded to each other (ML2) among the triglycerides that make up the oil composition Measurements were performed based on the Standard Method for Analysis of Fats and Oils (2.4.6.1-2013, triacylglycerol composition). The gas chromatography device used was a GC-2010 model manufactured by Shimadzu Corporation. The column used was a DB-1 manufactured by GL Sciences.

[0063] The analytical values ​​of the above triglyceride fractions for lard and MPO are shown in Table 1.

[0064] [Table 1]

[0065] <Mouse group> C57BL6J mice (male, 8 weeks old) were divided into four test groups, A to D (six mice per group), and were fed the test diets shown in Table 2 ad libitum for eight weeks.

[0066] [Table 2]

[0067] Below, the data in each graph is shown as the mean value ± standard error. A two-way analysis of variance (difference in oil type x intake of oil and fat) was performed on each data, and if the interaction between the two factors was significant, a multiple comparison test was performed. In addition, 5% was set as the criterion for detecting significance.

[0068] <Body weight, adipose tissue weight, and food intake> Body weight and food intake (g / day / mouse) were measured weekly. In addition, peritedimeric adipose tissue was collected at the time of dissection and weighed.

[0069] Figure 1 shows the final body weight (body weight after 8 weeks of feeding) of each mouse group. Figure 2 shows the weight of testicular adipose tissue after 8 weeks of feeding of each mouse group. Figure 3 shows the amount of food fed (g / day / mouse). The 30% supplementation (groups B and D) significantly increased body weight and adipose tissue weight compared to the 7% supplementation (groups A and C), whereas no significant differences were observed between lard and MPO at either the 7% or 30% supplementation. No significant differences were observed between lard and MPO at either 7% or 30% feeding. These results indicate that there is no significant difference in body weight, adipose tissue weight, or feed intake between MPO and lard.

[0070] <Oral glucose tolerance test> After fasting for 12 hours, each group of mice was orally administered a glucose solution (2 mg / g mouse body weight), and blood glucose levels were measured over time before and 120 minutes after administration. Area under the curve (IAUC) was calculated from the data on blood glucose levels.

[0071] The results of the oral glucose tolerance test (IAUC for groups A to D) are shown in Figure 4. At 30% addition (comparison of groups C and D), MPO significantly reduced the IAUC compared to lard (Figure 4). These results indicate that MPO intake improves glucose tolerance more effectively than lard intake.

[0072] <Insulin tolerance test> After fasting for 2 hours, each group of mice was intraperitoneally administered an insulin solution (0.7mU / g mouse body weight), and blood glucose levels were measured over time before and up to 120 minutes after administration. Area under the curve (IAUC) was calculated from the blood glucose level transition data.

[0073] The IAUC in the insulin tolerance test is shown in Figure 5. In the insulin tolerance test, MPO significantly reduced the IAUC compared to lard, regardless of whether the IAUC was 7% or 30% added (Figure 5). These results indicate that MPO intake improves insulin sensitivity more effectively than lard intake.

[0074] <Assessment of binding between intestinal bacteria and intestinal IgA> Feces were suspended in phosphate buffer and intestinal bacteria were collected by stepwise centrifugation. Bacterial IgA was stained with FITC-labeled anti-IgA antibody, and bacterial nucleoid DNA was stained with propidium iodide (PI). After staining, IgA-binding bacteria were detected using a flow cytometer, and the ratio of IgA-binding bacteria (PI and FITC double positive bacteria) to all bacteria (PI positive bacteria) (IgA coating rate) was calculated.

[0075] Representative images of flow cytometer analysis are shown in Figure 6. All bacteria (PI-positive bacteria) are enclosed in a thick frame, and IgA-binding bacteria (PI, FITC double-positive bacteria) are enclosed in a thin frame. The IgA coating rates for groups A to D are shown in Figure 7. At both 7% and 30% addition, MPO significantly increased the IgA coating rate compared to lard. This result indicates that MPO intake more effectively promotes IgA binding to intestinal bacteria than lard intake.

[0076] <Measurement of elaidic acid concentration in feces> After freeze-drying the feces, lipids in the feces were extracted using a chloroform:methanol = 2:1 solution. Tridecanoic acid was added to the extracted lipids as an internal standard substance, and methyl esterification was performed based on the Standard Method for Fats and Oils Analysis (2.4.1.2-2013, boron trifluoride methanol method). The fatty acid composition was measured based on the Standard Method for Fats and Oils Analysis (2.2.4.3-2013, trans fatty acid content (capillary gas chromatography method)), and elaidic acid was identified by comparison with a standard product. The gas chromatography device used was a GC-2010 model manufactured by Shimadzu Corporation. The column used was an SP-2560 manufactured by SUPELCO.

[0077] Figure 8 shows the concentration of elaidic acid in the feces of mice in groups A to D. In a comparison of 30% addition (comparison between groups C and D), MPO significantly reduced the elaidic acid concentration in the feces compared to lard. This result indicates that, under high-volume oil intake, MPO effectively reduces the concentration of elaidic acid in the intestinal tract compared to lard.

[0078] <Measurement of active GLP1 concentration in plasma> Active glucagon-like peptide 1 (GLP1), secreted from L cells, an endocrine cell in the small intestine, promotes insulin secretion from the pancreas and is an essential hormone for maintaining normal glucose metabolism. Blood collected from mice by cardiac blood sampling was mixed with EDTA and centrifuged to collect plasma. The collected plasma was immediately mixed with a DPPIV inhibitor to suppress the degradation of GLP1. The concentration of active GLP1 in plasma was measured using the GLP-1, Active form (High Sensitivity) Assay Kit (IBL).

[0079] Figure 9 shows the concentration of active GLP1 in the plasma of mice in groups A to D. In both the 7% and 30% additions, MPO significantly increased the plasma concentration of active GLP1 compared to lard. This result indicates that MPO promotes GLP1 secretion more effectively than lard.

[0080] <Quantitative analysis of colonic inflammatory cytokine CXCL1 gene expression levels> Total RNA was extracted and purified from the colon using Isogen2 (Nippon Gene). cDNA was synthesized by reverse transcription using RevertraAce (Toyobo). Gene-specific primers and a DNA polymerase solution for quantitative PCR were added to the synthesized cDNA as a template, and the gene expression level of the inflammatory cytokine CXCL1 was relatively quantified using the SYBR method.

[0081] Figure 10 shows the expression levels of CXCL1 mRNA in mice from groups A to D. Compared to lard, MPO significantly reduced the expression levels of CXCL1 gene in the colon when added at either 7% or 30%. These results indicate that MPO effectively suppresses the expression of CXCL1, one of the inflammatory cytokines, compared to lard. [Industrial Applicability]

[0082] According to the present invention, it is possible to provide oils and fats for improving abnormal glucose metabolism and oils and fats for improving intestinal environment.

Claims

1. An oil for improving abnormal sugar metabolism, comprising an oil composition, the oil composition containing palmitic acid in an amount of 10% by mass or more and 30% by mass or less of all constituent fatty acid residues of the oil composition, and the palmitic acid bonded to the 2-position being 50% by mass or more of the palmitic acid.

2. The oil and fat composition contains medium-chain fatty acids in all of the constituent fatty acid residues of the oil and fat composition. The oil or fat for improving abnormal sugar metabolism according to claim 1.

3. The oil or fat for improving abnormal glucose metabolism according to claim 1, which improves abnormal glucose metabolism by promoting binding between intestinal bacteria and IgA in the intestine.

4. The oil or fat for improving abnormal sugar metabolism according to claim 1, which improves abnormal sugar metabolism by lowering the concentration of elaidic acid in the intestine.

5. The oil or fat for improving abnormal glucose metabolism according to claim 1, which improves abnormal glucose metabolism by promoting secretion of GLP1.

6. The oil and fat composition contains, among the triglycerides constituting the oil and fat composition, a triglyceride having two molecules of medium-chain fatty acid and one molecule of long-chain fatty acid bonded thereto, and a triglyceride having one molecule of medium-chain fatty acid and two molecules of long-chain fatty acid bonded thereto, in a total amount of 50 mass% or more. The oil or fat for improving abnormal sugar metabolism according to claim 1.

7. The oil and fat composition for improving abnormal sugar metabolism according to claim 1, which is an oil and fat composition obtained by 1,3-position specific interesterification of the following raw oil and fat compositions (A) and (B): (A) A triglyceride containing 70% by mass or more of medium-chain fatty acids among all the constituent fatty acid residues. (B) A triglyceride containing 15% by mass or more of palmitic acid among all of the constituent fatty acid residues.

8. The medium chain fatty acid is caprylic acid and / or capric acid. The oil or fat for improving abnormal sugar metabolism according to claim 1.

9. The oil or fat for improving glucose metabolism disorders according to any one of claims 1 to 8 is contained therein. Oral or parenteral compositions.

10. An oil and fat for improving intestinal environment, comprising an oil and fat composition, the oil and fat composition containing palmitic acid in an amount of 10% by mass or more and 30% by mass or less of all constituent fatty acid residues of the oil and fat composition, and the palmitic acid bonded to the 2-position being 50% by mass or more of the palmitic acid.

11. The oil and fat composition contains medium-chain fatty acids in all of the constituent fatty acid residues of the oil and fat composition. The oil or fat for improving intestinal environment according to claim 10.

12. The oil or fat for improving intestinal environment according to claim 10, which is an oil or fat for promoting binding between intestinal bacteria and intestinal IgA.

13. The oil or fat for improving intestinal environment according to claim 10, which is an oil or fat for suppressing intestinal inflammation.

14. The oil and fat composition contains, among the triglycerides constituting the oil and fat composition, a triglyceride having two molecules of medium-chain fatty acid and one molecule of long-chain fatty acid bonded thereto, and a triglyceride having one molecule of medium-chain fatty acid and two molecules of long-chain fatty acid bonded thereto, in a total amount of 50 mass% or more. The oil or fat for improving intestinal environment according to claim 10.

15. The oil and fat composition for improving intestinal environment according to claim 10, which is obtained by 1,3-position specific interesterification of the following raw oil and fat compositions (A) and (B): (A) A triglyceride containing 70% by mass or more of medium-chain fatty acids among all the constituent fatty acid residues. (B) A triglyceride containing 15% by mass or more of palmitic acid among all of the constituent fatty acid residues.

16. The medium chain fatty acid is caprylic acid and / or capric acid. The oil or fat for improving intestinal environment according to claim 10.

17. The oil or fat for improving intestinal environment according to any one of claims 10 to 16 is contained therein. Oral or parenteral compositions.

Images